The Role of Quantitative Polymerase Chain Reaction in the Diagnosis of Pneumocystis jirovecii Pneumonia in Immunocompromised patients: A Pilot Study

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

TCTR

Registry ID

TCTR20250915009

Enrollment

Registered

2025-09-15

Start date

2025-06-10

Completion date

Unknown

Last updated

2026-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Immunocompromised patients with suspected pneumonia Pneumonia, pneumocystosis, immunocompromised

Interventions

We measured PCP DNA load in bronchoalveolar fluid in those with PCP and non-PCP patients then compare.

Active Comparator Other

Single Group Assignment

Eligibility

Sex/Gender

All

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Immuncompromised hosts Infectious pneumonia as a cause

Exclusion criteria

Exclusion criteria: Denied to participate

Design outcomes

Primary

Measure	Time frame
PCP load for PCP diagnosis at diagnosis compare to giemsa staining or fluorescence staining	—

Secondary

Measure	Time frame
Mortality 30, 60 and 90 days after diagnosis both direct and non-direct cause of mortality from PCP	—

Countries

Thailand

Contacts

Public ContactPoj Patumnakul

Faculty of Medicine Ramathibodi Hospital

pojidarkstar@gmail.com6622011581

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Apr 4, 2026